查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930114

精神分裂症药物市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察，2026-2034 年

Schizophrenia Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 134 Pages | 商品交期: 请询问到货日

价格

精神分裂症药物市场成长因素

全球精神分裂症药物市场在中枢神经系统 (CNS) 治疗领域占重要占有率，用于治疗严重影响认知、情绪和行为功能的严重慢性精神疾病。精神分裂症被归类为精神病性障碍，其特征是妄想、幻觉、思维混乱和判断力受损等症状。虽然精神分裂症无法治愈，但可以透过终身药物治疗（主要使用抗精神病药物）有效控制病情。

市场规模及预测

根据 Fortune Business Insights 数据显示，2025 年全球精神分裂症药物市场规模为 90.8 亿美元。预计到 2026 年将达到 94.8 亿美元，到 2034 年将成长至 134.1 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 4.43%。

市场稳定成长得益于疾病认知度的提高、诊断率的上升、先进抗精神病疗法的广泛应用以及药物研发的持续创新。

市场概览

即使症状缓解，精神分裂症也需要长期使用抗精神病药物治疗以防止復发。这些药物主要透过调节大脑中的多巴胺活性来发挥作用。在过去几十年，精神分裂症的治疗经历了从第一代（典型）抗精神病药物到第二代和第三代（非典型）抗精神病药物的重大转变。这种转变主要得益于疗效和副作用的改善。

第一代抗精神病药物有时伴随严重的锥体外系副作用，例如肌强直、震颤、静坐不能、肌张力失调和迟发性运动障碍。这些限制加速了安全性更高的新药的普及应用。

主要市场驱动因子

精神分裂症治疗市场的主要驱动因素之一是人们对精神疾病的认识不断提高，这得益于政府的各项举措和医疗改革。在美国等国家，联邦和州立法规定精神科医疗和身体健康医疗的报销待遇必须相同，从而提高了患者获得先进精神分裂症治疗的机会。

另一个关键驱动因素是强大的研发管线，儘管面临监管和临床试验方面的挑战，目前仍有多种药物正在研发中。该行业的关注点正日益转向復发率低、患者依从性高且副作用小的治疗方法。

向长效注射剂 (LAI) 的过渡

口服抗精神病药物的顺从性低是精神分裂症治疗的一大挑战，这通常会导致症状復发和不可逆的认知障碍。这加速了长效注射剂 (LAI) 抗精神病药物的引入，预计这些药物将提高依从性并降低復发率。

预计到 2026 年，注射疗法将占市场占有率的 73.46%，凸显了其日益增长的临床重要性。 FDA 批准 Perseris（利培酮缓释片）等药物进一步巩固了这一趋势。

市场区隔分析

依治疗类别

市场细分为第二代、第三代和其他抗精神病药物。

由于疗效显着且副作用极小，预计第二代抗精神病药物在预测期内将创造最高的收入。

包括阿立哌唑（Abilify）和阿立哌唑维持治疗（Abilify Maintena）在内的第三代药物也贡献显着，而第一代药物仍然对难治性患者有效。

依治疗方法

精神分裂症的治疗分为口服和注射疗法。

由于依从性提高和復发风险降低，注射药物市场成长更快。然而，预计到2026年，口服製剂将占市场占有率的85.21%，反映出其持续的受欢迎程度。

依通路划分

预计到 2026 年，医院药局将占市场主导地位，市占率将达到 38.55%。这主要得益于精神科医生主导的治疗以及长效注射剂 (LAI) 的使用。其次是零售药局和网路药局，其中网路药局预计将实现最高的复合年增长率，这主要得益于数位化通路的日益普及。

区域分析

北美地区在2025年占了精神分裂症治疗市场62.91%的占有率，预计到2026年，其市场收入将达到59.7亿美元。光是美国市场预计到2026年就将达到56.7亿美元，主要得益于先进的治疗方法和有利的报销政策。

亚太地区预计将实现最高成长，预计到2026年，日本将达到5.8亿美元，中国将达到3.9亿美元，印度将达到1.9亿美元。欧洲市场也呈现稳定成长，其中德国、英国和法国是主要成长动力。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 长效注射剂（LAI）治疗应用日益普及
  • 各地区精神分裂症盛行率
  • 新产品上市
  • 在开发产品分析
  • 各地区监理环境
  • 第一代抗精神病药物与第二代和第三代抗精神病药物的比较分析
  • 研发计画概述精神分裂症治疗

第五章：全球精神分裂症治疗市场分析、洞察与预测（2021-2034）

  • 主要发现/摘要
  • 市场分析、洞察与预测 - 按治疗类别划分
    • 第三代抗精神病药物
    • 第二代抗精神病药物
    • 其他
  • 市场分析、洞察与预测 - 按治疗类别划分
    • 口服
    • 注射
  • 市场分析、洞察与预测 - 按分销管道划分
    • 医院药房
    • 零售药房
    • 线上药房
    • 其他
  • 市场分析、洞察与预测 - 按区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美精神分裂症药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲精神分裂症药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 其他地区欧洲

第八章 亚太地区精神分裂症药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲精神分裂症药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲精神分裂症药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 主要行业趋势
  • 全球市占率分析（2025）
  • 竞争格局概览
  • 主要公司比较分析
  • 公司简介
    • H.灵北製药股份有限公司
    • 大冢製药株式会社
    • 强生製药股份有限公司
    • 礼来公司
    • 阿斯特捷利康
    • 艾尔建
    • 万达製药股份有限公司
    • 住友製药株式会社
    • Alkermes plc
    • 百时美施贵宝公司
    • 其他主要公司

第十二章：策略建议

Product Code: FBI101531

Growth Factors of schizophrenia drugs Market

The global schizophrenia drugs market represents a critical segment of the central nervous system (CNS) therapeutics landscape, addressing a severe and chronic psychiatric disorder that significantly impacts cognitive, emotional, and behavioral functioning. Schizophrenia is classified as a psychotic disorder and is characterized by symptoms such as delusions, hallucinations, disorganized thinking, and impaired judgment. Although the condition cannot be cured, it can be effectively managed through lifelong pharmacological treatment, primarily using antipsychotic medications.

Market Size and Forecast

According to Fortune Business Insights, the global schizophrenia drugs market was valued at USD 9.08 billion in 2025. The market is projected to reach USD 9.48 billion in 2026 and further expand to USD 13.41 billion by 2034, registering a CAGR of 4.43% during the forecast period (2026-2034).

The steady growth of the market is supported by rising disease awareness, increasing diagnosis rates, growing adoption of advanced antipsychotic therapies, and continuous innovation in drug development.

Market Overview

Schizophrenia requires long-term treatment with antipsychotic drugs, even after symptom remission, to prevent relapse. These medications primarily act by regulating dopamine activity in the brain. Over recent decades, schizophrenia treatment has undergone a major transition from first-generation (typical) antipsychotics to second- and third-generation (atypical) antipsychotics, driven by improved efficacy and reduced side-effect profiles.

First-generation antipsychotics were associated with severe extrapyramidal side effects such as rigidity, tremors, akathisia, dystonia, and tardive dyskinesia. These limitations accelerated the adoption of newer drug classes with better safety outcomes.

Key Market Drivers

One of the primary drivers of the schizophrenia drugs market is increased awareness of mental health disorders, supported by government initiatives and healthcare reforms. In countries such as the United States, federal and state mandates require parity in reimbursement for mental and physical healthcare, improving patient access to advanced schizophrenia treatments.

Another major driver is the strong R&D pipeline, with several drugs under development despite regulatory and clinical trial challenges. The industry focus is increasingly shifting toward treatments with fewer relapses, better patient adherence, and minimal adverse effects.

Shift Toward Long-Acting Injectables (LAIs)

Non-adherence to oral antipsychotic medication is a major challenge in schizophrenia treatment and often leads to symptom relapse and irreversible cognitive damage. This has accelerated the adoption of long-acting injectable (LAI) antipsychotics, which improve adherence and reduce relapse rates.

In 2026, injectable-based treatments are projected to account for a 73.46% market share, highlighting their growing clinical importance. FDA approvals such as Perseris (extended-release risperidone) further reinforce this trend.

Market Segmentation Analysis

By Therapeutic Class

The market is segmented into second-generation, third-generation, and other antipsychotics.

The second-generation antipsychotics segment is expected to generate the highest revenue during the forecast period due to superior efficacy and fewer side effects.

Third-generation drugs, including ABILIFY and ABILIFY MAINTENA, also contribute significantly, while first-generation drugs remain relevant for treatment-resistant patients.

By Treatment Type

Schizophrenia treatment is categorized into oral and injectable therapies.

The injectable segment is witnessing faster growth due to better adherence and reduced relapse risk. However, oral formulations are projected to account for 85.21% market share in 2026, reflecting their continued widespread use.

By Distribution Channel

Hospital pharmacies dominated the market, accounting for 38.55% share in 2026, supported by psychiatrist-led treatment and administration of LAIs. Retail and online pharmacies follow, with online pharmacies expected to register the highest CAGR due to increasing digital access.

Regional Analysis

North America dominated the schizophrenia drugs market with a 62.91% share in 2025, generating USD 5.97 billion in revenue in 2026. The U.S. market alone is projected to reach USD 5.67 billion by 2026, driven by advanced therapeutics and favorable reimbursement policies.

The Asia Pacific region is expected to witness the highest growth, with Japan reaching USD 0.58 billion, China USD 0.39 billion, and India USD 0.19 billion by 2026. Europe is also experiencing steady growth, led by Germany, the U.K., and France.

Competitive Landscape

Key players include H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Alkermes plc, and Bristol-Myers Squibb Company. Market participants are actively investing in LAIs, next-generation antipsychotics, and novel mechanisms such as muscarinic receptor agonists.

Conclusion

In conclusion, the global schizophrenia drugs market is expected to grow steadily from USD 9.08 billion in 2025 to USD 13.41 billion by 2034, driven by increasing mental health awareness, strong R&D pipelines, and rising adoption of second- and third-generation antipsychotics. The growing preference for long-acting injectable therapies and supportive healthcare policies will continue to improve treatment outcomes and sustain long-term market growth across both developed and emerging regions.

Segmentation By Therapeutic Class

  • Second Generation
  • Third Generation
  • Others

By Treatment

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Increasing Adoption of Long Acting Injectable (LAIs) as a Form of Treatment
  • 4.2. Prevalence of Schizophrenia Disorders by Key Regions
  • 4.3. New Product Launches
  • 4.4. Pipeline Analysis
  • 4.5. Regulatory Scenario By Key Regions
  • 4.6. Analysis of First Generation Antipsychotics versus Second & Third Generation Antipsychotics
  • 4.7. Overview of R&D Initiatives in Schizophrenia Treatment

5. Global Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 5.2.1. Third Generation Antipsychotics
    • 5.2.2. Second Generation Antipsychotics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Treatment
    • 5.3.1. Oral
    • 5.3.2. Injectable
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapeutic Class
    • 6.2.1. Third Generation Antipsychotics
    • 6.2.2. Second Generation Antipsychotics
    • 6.2.3. Others
  • 6.3. Market Analysis - By Treatment
    • 6.3.1. Oral
    • 6.3.2. Injectable
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapeutic Class
    • 7.2.1. Third Generation Antipsychotics
    • 7.2.2. Second Generation Antipsychotics
    • 7.2.3. Others
  • 7.3. Market Analysis - By Treatment
    • 7.3.1. Oral
    • 7.3.2. Injectable
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapeutic Class
    • 8.2.1. Third Generation Antipsychotics
    • 8.2.2. Second Generation Antipsychotics
    • 8.2.3. Others
  • 8.3. Market Analysis - By Treatment
    • 8.3.1. Oral
    • 8.3.2. Injectable
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapeutic Class
    • 9.2.1. Third Generation Antipsychotics
    • 9.2.2. Second Generation Antipsychotics
    • 9.2.3. Others
  • 9.3. Market Analysis - By Treatment
    • 9.3.1. Oral
    • 9.3.2. Injectable
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Therapeutic Class
    • 10.2.1. Third Generation Antipsychotics
    • 10.2.2. Second Generation Antipsychotics
    • 10.2.3. Others
  • 10.3. Market Analysis - By Treatment
    • 10.3.1. Oral
    • 10.3.2. Injectable
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country/ Sub-Region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles
    • 11.5.1. H. Lundbeck A/S
      • 11.5.1.1. Overview
      • 11.5.1.2. Products & services
      • 11.5.1.3. SWOT Analysis
      • 11.5.1.4. Recent Developments
      • 11.5.1.5. Strategies
      • 11.5.1.6. Financials (Based on Availability)
    • 11.5.2. Otsuka Pharmaceutical Co., Ltd.
      • 11.5.2.1. Overview
      • 11.5.2.2. Products & services
      • 11.5.2.3. SWOT Analysis
      • 11.5.2.4. Recent Developments
      • 11.5.2.5. Strategies
      • 11.5.2.6. Financials (Based on Availability)
    • 11.5.3. Janssen Pharmaceuticals, Inc.
      • 11.5.3.1. Overview
      • 11.5.3.2. Products & services
      • 11.5.3.3. SWOT Analysis
      • 11.5.3.4. Recent Developments
      • 11.5.3.5. Strategies
      • 11.5.3.6. Financials (Based on Availability)
    • 11.5.4. Eli Lilly and Company
      • 11.5.4.1. Overview
      • 11.5.4.2. Products & services
      • 11.5.4.3. SWOT Analysis
      • 11.5.4.4. Recent Developments
      • 11.5.4.5. Strategies
      • 11.5.4.6. Financials (Based on Availability)
    • 11.5.5. AstraZeneca
      • 11.5.5.1. Overview
      • 11.5.5.2. Products & services
      • 11.5.5.3. SWOT Analysis
      • 11.5.5.4. Recent Developments
      • 11.5.5.5. Strategies
      • 11.5.5.6. Financials (Based on Availability)
    • 11.5.6. ALLERGAN
      • 11.5.6.1. Overview
      • 11.5.6.2. Products & services
      • 11.5.6.3. SWOT Analysis
      • 11.5.6.4. Recent Developments
      • 11.5.6.5. Strategies
      • 11.5.6.6. Financials (Based on Availability)
    • 11.5.7. Vanda Pharmaceuticals Inc.
      • 11.5.7.1. Overview
      • 11.5.7.2. Products & services
      • 11.5.7.3. SWOT Analysis
      • 11.5.7.4. Recent Developments
      • 11.5.7.5. Strategies
      • 11.5.7.6. Financials (Based on Availability)
    • 11.5.8. Sumitomo Dainippon Pharma Co., Ltd.
      • 11.5.8.1. Overview
      • 11.5.8.2. Products & services
      • 11.5.8.3. SWOT Analysis
      • 11.5.8.4. Recent Developments
      • 11.5.8.5. Strategies
      • 11.5.8.6. Financials (Based on Availability)
    • 11.5.9. Alkermes plc
      • 11.5.9.1. Overview
      • 11.5.9.2. Products & services
      • 11.5.9.3. SWOT Analysis
      • 11.5.9.4. Recent Developments
      • 11.5.9.5. Strategies
      • 11.5.9.6. Financials (Based on Availability)
    • 11.5.10. Bristol-Myers Squibb Company
      • 11.5.10.1. Overview
      • 11.5.10.2. Products & services
      • 11.5.10.3. SWOT Analysis
      • 11.5.10.4. Recent Developments
      • 11.5.10.5. Strategies
      • 11.5.10.6. Financials (Based on Availability)
    • 11.5.11. Other Prominent Players
      • 11.5.11.1. Overview
      • 11.5.11.2. Products & services
      • 11.5.11.3. SWOT Analysis
      • 11.5.11.4. Recent Developments
      • 11.5.11.5. Strategies
      • 11.5.11.6. Financials (Based on Availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 2: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 3: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 6: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 7: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 10: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 11: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 14: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 15: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 18: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 19: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 22: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 23: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Schizophrenia Drugs Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025 & 2034
  • Figure 3: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Second Generation, 2021-2034
  • Figure 4: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Third Generation, 2021-2034
  • Figure 5: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 6: Global Schizophrenia Drugs Market Value Share (%), by Treatment, 2025 & 2034
  • Figure 7: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Oral, 2021-2034
  • Figure 8: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Injectable, 2021-2034
  • Figure 9: Global Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 10: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 11: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 12: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 13: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 14: Global Schizophrenia Drugs Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 15: North America Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 16: North America Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 17: North America Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 18: North America Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 19: North America Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Schizophrenia Drugs Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 22: North America Schizophrenia Drugs Market Value Share (%), By Country, 2025
  • Figure 23: Europe Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 24: Europe Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 25: Europe Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 26: Europe Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 27: Europe Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 28: Europe Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Europe Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Europe Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 32: Asia Pacific Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 33: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 34: Asia Pacific Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 35: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 36: Asia Pacific Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Asia Pacific Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Latin America Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 40: Latin America Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 41: Latin America Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 42: Latin America Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 43: Latin America Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 48: Middle East & Africa Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 49: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 50: Middle East & Africa Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 51: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 52: Middle East & Africa Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Middle East & Africa Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Global Schizophrenia Drugs Market Share (%), By Company, 2025